Sagitta Biotech is developing a pipeline of vaccines and oncology products

Sagitta Biotech is driven to address unmet needs in the vaccine, oncology, and gene therapy fields.

To this end, Sagitta Biotech is building its pipeline using a non-replicating active virosome platform that is specifically designed to be safe, effective, and easily manufacturable. It has a wide range of potential applications in vaccine development and targeted cancer or gene therapy.

The platform is highly versatile and can be easily manipulated using a cassette system to express a wide array of antigens and payloads specifically into the target cells. This active virosome technology allows for rapid development and production using existing manufacturing infrastructure.

We also offer use of our platform for co-development of custom vaccines, oncology, and gene therapy products, acting as a technology provider or subcontracting partner.

MANAGEMENT

Dr. Benjamin DAMIEN (PhD, MBA)

Chief Executive Officer

  • 23 years in biotech management and drug  development (BioXpr, Targetome, Univercells,  Delta Diagnostics).

  • Vaccine development and immune-oncology expert

  • Raised over 35M€ from dilutive and non-dilutive  sources and participated to the creation of 15  biotech startups in Europe.

Dr. Hélène GAZON (PhD)

Chief Scientific Officer

  • Expert in Immunology – Oncology and viral vectors

  • 10 years of experience in vaccine and oncology development (PDC*Line)

Board of directors

Didier ALLAER

Chairman of the Board

  • Business Angel

  • Founder of Diagenode, and board  member of several startups in Biotech/medtech

Frederic SCHYNTS

Director (representing NOSHAQ)

  • 25 years of experience in virology, immunology  and vaccine development (GSK Vaccines)

  • Independent consultant in drug and biological  developments

Philippe MONTEYNE

Independent Director

  • 20 years of experience in Biotech & Pharma  (GSK, Sanofi)

  • Developed Cervarix End-to-End

  • VC  Fund Partner (Fund+, Aliath, AltamarCAM)